CD20 Rituximab Biosimilar anti-Human, Unconjugated, Clone: Rituximab.rMAb (also known as Rituximab Biosimilar), BD Phrmingen™

Biosimilar Monoclonal Antibody

Supplier:  BD Biosciences 569496

Catalog No. BDB569496

Description

CD20 Rituximab Biosimilar Monoclonal antibody specifically detects CD20 Rituximab Biosimilar in Human samples. It is validated for Flow cytometry|Cytotoxicity

Specifications

• Antigen: CD20 Rituximab Biosimilar
• Classification: Monoclonal
• Concentration: 1.0 mg/mL
• Formulation: No azide/low endotoxin: Aqueous buffered solution containing no preservative, 0.2 μm sterile filtered. Endotoxin level is ≤0.1 EU/μg (≤0.01 ng/μg) of protein as determined by the LAL assay.
• Immunogen: Human CD20
• Quantity: 0.5 mg
• Primary or Secondary: Primary
• Target Species: Human
• Form: Liquid

• Applications: Flow Cytometry, Cytotoxicity Assay
• Clone: Rituximab.rMAb (also known as Rituximab Biosimilar)
• Conjugate: Unconjugated
• Gene Alias: B1; Bp35; LEU-16; MS4A1
• Purification Method: Affinity Chromatography
• Regulatory Status: RUO
• Gene ID (Entrez): 931
• Content And Storage: Store undiluted at 4°C. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. This preparation contains no preservatives, thus it should be handled under aseptic conditions.
• Isotype: IgG1 κ